These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 22716155)
1. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Schoedel KA; Harrison SJ Curr Pharm Des; 2012; 18(32):5008-14. PubMed ID: 22716155 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456 [TBL] [Abstract][Full Text] [Related]
3. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis. Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691 [TBL] [Abstract][Full Text] [Related]
4. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N; BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349 [TBL] [Abstract][Full Text] [Related]
5. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. van Amsterdam J; Brunt T; van den Brink W J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398 [TBL] [Abstract][Full Text] [Related]
6. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930 [TBL] [Abstract][Full Text] [Related]
7. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Arnold JC; Boucher AA; Karl T Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133 [TBL] [Abstract][Full Text] [Related]
8. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Robson P Expert Opin Drug Saf; 2011 Sep; 10(5):675-85. PubMed ID: 21542664 [TBL] [Abstract][Full Text] [Related]
9. Cannabis-associated psychosis: Neural substrate and clinical impact. Murray RM; Englund A; Abi-Dargham A; Lewis DA; Di Forti M; Davies C; Sherif M; McGuire P; D'Souza DC Neuropharmacology; 2017 Sep; 124():89-104. PubMed ID: 28634109 [TBL] [Abstract][Full Text] [Related]
10. A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. Überall MA J Pain Res; 2020; 13():399-410. PubMed ID: 32104061 [TBL] [Abstract][Full Text] [Related]
11. Cannabis; adverse effects from an oromucosal spray. Scully C Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180 [TBL] [Abstract][Full Text] [Related]
12. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS. Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310 [TBL] [Abstract][Full Text] [Related]
13. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881 [TBL] [Abstract][Full Text] [Related]
14. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review. Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997 [TBL] [Abstract][Full Text] [Related]
15. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Deiana S Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356 [TBL] [Abstract][Full Text] [Related]
17. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Morgan CJ; Curran HV Br J Psychiatry; 2008 Apr; 192(4):306-7. PubMed ID: 18378995 [TBL] [Abstract][Full Text] [Related]
18. Δ Silveira MM; Adams WK; Morena M; Hill MN; Winstanley CA J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177 [TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of cannabinoids: Forensic aspects. Indorato F; Liberto A; Ledda C; Romano G; Barbera N Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587 [TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]